| 摘要: |
| [摘要]目的：探讨重组人干扰素α-2b不同给药途径治疗婴幼儿毛细支气管炎的疗效及安全性。方法：回顾性分析我院2017年1月至2018年3月收治的符合纳入标准的毛细支气管炎患儿150例，采用随机数字表法分为对照组、雾化组和肌肉注射组各50例。三组患儿均给予常规治疗，雾化组加用雾化吸入重组人干扰素α-2b（每次100 000U/kg），肌肉注射组加用肌肉注射重组人干扰素α-2b（每次100 000U/kg-），比较两组患儿治疗前后血清白细胞介素-4（IL-4）、干扰素-γ（IFN-γ）水平，观察两组患儿临床疗效、临床症状体症消失时间及药物不良反应。结果：治疗后雾化组及肌肉注射组治疗总有效率高于对照组（P<0.05）；雾化组与肌肉注射组治疗总有效率比较差异无统计学意义（P>0.05）。随着时间的推移，三组患儿IL-4、IFN-γ均降低，差异均有统计学意义（P<0.05）；治疗前三组患儿IL-4、IFN-γ差异均无统计学意义（P>0.05），治疗后雾化组和肌肉注射组IL-4、IFN-γ水平均低于对照组（P<0.05），雾化组IL-4、IFN-γ水平低于肌肉注射组（P<0.05）。雾化组患儿总病程、咳嗽消失时间、干湿啰音消失时间、住院时间、喘息消失时间均较肌肉注射组缩短，差异有统计学意义（P<0.05）。雾化组患儿有1例食欲不振、1例肝功能受损及1例血小板减少；肌肉注射组有2例发热、3例食欲不振、1例肝功能受损、3例血小板减少及3例注射部位局部红斑；雾化组不良反应发生率低于肌肉注射组（P<0.05）。结论：重组干扰素α-2b治疗婴幼儿毛细支气管炎具有较好疗效，可有效改善患儿炎症因子水平，雾化吸入有利于缩短病程，较肌肉注射更加安全。 |
| 关键词: 重组干扰素α-2b 毛细支气管炎 给药途径 婴幼儿 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2020.09.006 |
|
| 基金项目: |
|
| Recombinant Human Interferon α-2b in the Treatment of Infants with Bronchiolitis by Different Routes of Administration |
| Yuan Yin, Peng Hua |
| (Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Hubei Wuhan 430022, China) |
| Abstract: |
| [Abstract] Objective: To investigate the efficacy and safety of recombinant human interferon α-2b in the treatment of infants with bronchiolitis by different routes of administration. Methods: A total of 150 children with bronchiolitis admitted to our hospital from Jan. 2017 to Mar. 2018 were retrospectively extracted to be divided into the control group, atomization group and intramuscular injection group via the random number table, with 50 cases in each group. Three groups were given conventional treatment. Recombinant human interferon α-2b (100,000 U/kg) by ultrasonic atomizing inhalation was added to atomization group. Recombinant human interferon α-2b (100,000 U/kg) by intramuscular injection was added to intramuscular injection group. The levels of interleukin-4 (IL-4), interferon-γ (IFN-γ) in the atomization group and intramuscular injection group were collected and analyzed before and after treatment. Clinical efficacy, disappearance time of clinical symptoms and adverse drug reactions of the atomization group and intramuscular injection group were observed. Results: After treatment, the total effective rate of the atomization group and the intramuscular injection group was higher than that of the control group (P<0.05), the total effective rate of the atomization group and the intramuscular injection group was not statistically different (P>0.05). The levels of IL-4 and IFN-γ of three groups decreased after treatment, and the differences were statistically significant (P<0.05). There was no significant difference in IL-4 and IFN-γ in three groups before treatment (P>0.05). After treatment, the levels of IL-4 and IFN-γ in the atomization group and the intramuscular injection group were lower than those in the control group (P<0.05), the levels of IL-4 and IFN-γ in the atomization group were lower than those in the intramuscular injection group (P<0.05). The total course of disease, the disappearance time of cough and lung rales, the length of stay, and the disappearance time of wheezing in the atomization group were all shorter than those in the intramuscular injection group, and the difference was statistically significant (P<0.05). In the atomization group, there were 1 case of loss of appetite, 1 case of liver dysfunction, and 1 case of thrombocytopenia. While the intramuscular injection group had 2 cases of fever, 3 cases of loss of appetite, 1 case of liver dysfunction, 3 cases of thrombocytopenia, and 3 cases of local erythema at the injection site. The incidence of adverse drug reactions in the atomization group was lower than that in the intramuscular injection group (P<0.05). Conclusion: Recombinant human interferon α-2b has significant curative effects in the treatment of infants with bronchiolitis and can effectively improve the level of inflammatory factors. Aerosol inhalation is beneficial to shorten the course of the disease and is safer than intramuscular injection. |
| Key words: recombinant interferon α-2b bronchiolitis route of administration infants |
